Troy Cox
CIK 1696923 · Executive Chair · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.52M
Companies
6
Total Filings
29
Lifetime Open-Market Net
-$2.98M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MPLT | Director | 7,864 | $15.12 | $118.9K | $0 | 1 | 2026-06-25 |
| LAB | Director | 475,702 | $0.87 | $415.7K | $0 | 7 | 2026-06-23 |
| SOPH | Director | 328,743 | $5.54 | $1.82M | $0 | 1 | 2026-06-22 |
| ZYME | Director | 7,500 | $21.95 | $164.6K | $348.8K | 6 | 2024-12-12 |
| SomaLogic, Inc. (SLGCW) Delisted | Executive Chair | 106,930 | $0.09 | $9.2K | $0 | 5 | 2023-03-22 |
| Foundation Medicine, Inc. (FMI) Delisted | Chief Executive Officer | 242,068 | — | — | -$3.33M | 7 | 2018-07-05 |
Recent Filings · Page 2 of 3
29 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-09 | — | Disp (D) | −78,430 | $0 | |
| 2023-12-08 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2023-03-22 | SomaLogic, Inc. (SLGCW) Delisted | Grant (A) | +28,500 | $0 | EDGAR |
| 2022-12-23 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2022-10-18 | SomaLogic, Inc. (SLGCW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-03 | SomaLogic, Inc. (SLGCW) Delisted | Grant (A) | +3,430 | $0 | EDGAR |
| 2021-12-13 | SomaLogic, Inc. (SLGCW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-03 | SomaLogic, Inc. (SLGCW) Delisted | Mixed | +75,000 | $500.0K | EDGAR |
| 2021-05-07 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2020-05-12 | ZYME | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.